Vaxcyte (PCVX) Corporate presentation summary

Mission and platform overview

• Focused on engineering high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) enabling rapid, flexible, and scalable vaccine development.

• Platform allows site-specific conjugation, producing carrier-sparing conjugates and enabling broader-spectrum vaccines.

Pneumococcal conjugate vaccine (PCV) franchise

• VAX-31 is a 31-valent PCV designed to cover 95% of invasive pneumococcal disease (IPD) in U.S. adults, surpassing current standards.

• VAX-24 is a 24-valent PCV for infants, showing strong immunogenicity and safety in Phase 2 studies.

• Both VAX-31 and VAX-24 leverage carrier-sparing technology to minimize immune suppression and maximize serotype coverage.

• Phase 3 adult trials (OPUS-1, OPUS-2, OPUS-3) for VAX-31 are fully enrolled, with topline data expected by end of October 2026.

• VAX-31 and VAX-24 demonstrate robust immune responses and safety profiles comparable to or better than existing PCVs.

Market opportunity and adoption drivers

• Global pneumococcal vaccine market is ~$8B, expected to grow to ~$12B by 2030, driven by expanded adult recommendations.

• Broader serotype and disease coverage is the primary driver of adoption, with rapid uptake seen for higher-valency PCVs.

• VAX-31 and VAX-24 are positioned to address unmet needs in both adult and pediatric populations, with potential for best-in-class status.

• Commercial strategy targets retail pharmacies and large health systems, which account for the majority of adult PCV volume.